TCDD에 노출된 갑상샘 유두암종 세포주에서 선택적 Cyclooxygenase 2 억제제의 효과
Effect of Selective Cyclooxygenase 2 Inhibitor in TCDD Pre-exposed Thyroid Papillary Carcinoma Cell Line
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Cyclooxygenase 2 (COX-2) is related to carcinogenesis and progression of cancer. COX-2 has been detected in thyroid cancer. This suggests that COX-2 inhibitor may be useful to control the growth of thyroid cancer cells as well as the progression of thyroid cancer. Tetrachlorodibenzodioxin (TCDD), acting as an inflammatory cytokine, directly induces the expression of COX-2. We examine whether TCDD controls the effect of COX-2 inhibitor on thyroid cancer cells. Methods: The effects of TCDD and celecoxib on thyroid papillary carcinoma cell line (SNU790) were examined using cell proliferation and fluorescence-activated cell sorting analysis. Western blot analysis was performed to determine the expressed COX-2 levels and the cell cycle-related proteins. The matrix metalloproteinase-2 (MMP-2) expression and gelatinolytic activity were examined using real time-polymerase chain reaction and zymography. Results: TCDD directly induced the growth of SNU790 and the expression of cyclin D1, cyclin A, cyclin E, p21 and COX-2. Celecoxib suppressed the growth of SNU790 and the expression of cyclin D1 and cyclin E. Celecoxib reduced the MMP-2 expression and the gelatinolytic activity, but those effects were decreased in the SNU790 by either pre-treatment with TCDD or co-treatment with TCDD and celecoxib. Conclusions: Celocoxib effect is directly reduced depending on the exposure to TCDD. TCDD exposure should be considered in the treatment with Celecoxib.
Abstract
Background: Cyclooxygenase 2 (COX-2) is related to carcinogenesis and progression of cancer. COX-2 has been detected in thyroid cancer. This suggests that COX-2 inhibitor may be useful to control the growth of thyroid cancer cells as well as the progression of thyroid cancer. Tetrachlorodibenzodioxin (TCDD), acting as an inflammatory cytokine, directly induces the expression of COX-2. We examine whether TCDD controls the effect of COX-2 inhibitor on thyroid cancer cells. Methods: The effects of TCDD and celecoxib on thyroid papillary carcinoma cell line (SNU790) were examined using cell proliferation and fluorescence-activated cell sorting analysis. Western blot analysis was performed to determine the expressed COX-2 levels and the cell cycle-related proteins. The matrix metalloproteinase-2 (MMP-2) expression and gelatinolytic activity were examined using real time-polymerase chain reaction and zymography. Results: TCDD directly induced the growth of SNU790 and the expression of cyclin D1, cyclin A, cyclin E, p21 and COX-2. Celecoxib suppressed the growth of SNU790 and the expression of cyclin D1 and cyclin E. Celecoxib reduced the MMP-2 expression and the gelatinolytic activity, but those effects were decreased in the SNU790 by either pre-treatment with TCDD or co-treatment with TCDD and celecoxib. Conclusions: Celocoxib effect is directly reduced depending on the exposure to TCDD. TCDD exposure should be considered in the treatment with Celecoxib.
참고문헌 (29)
- Guarino V, "Thyroid cancer and inflammation", Mol Cell Endocrinol, 321, pp.94~102 (2010)
- Matsumura F, "The significance of the nongenomic pathway in mediating inflammatory signaling of the dioxin-activated Ah receptor to cause toxic effects", Biochem Pharmacol, 77, pp.608~626 (2009)
- Greenhough A, "The COX-2", PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment, 2009, pp.30, 377~386
- Eberhart CE, "Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas", Gastroenterology, 107, pp.1183~1188 (1994)
- Sano H, "Expression of cyclooxygenase- 1 and -2 in human colorectal cancer", Cancer Res, 55, pp.3785~3789 (1995)
- Agoff SN, "The role of cyclooxygenase 2 in ulcerative colitis-associated neoplasia", Am J Pathol, 157, pp.737~745 (2000)
- Koga H, "Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation", Hepatology, 29, pp.688~696 (1999)
- Sung JJ, "Cyclooxygenase-2 expression in Helicobacter pylori-associated premalignant and malignant gastric lesions", Am J Pathol, 157, pp.729~735 (2000)
- Zimmermann KC, "Cyclooxygenase-2 expression in human esophageal carcinoma", Cancer Res, 59, pp.198~204 (1999)
- Soslow RA, "COX-2 is expressed in human pulmonary, colonic, and mammary tumors", Cancer, 89, pp.2637~2645 (2000)
- Kune GA, "Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study", Cancer Res, 48, pp.4399~4404 (1988)
- Thun MJ, "Aspirin use and reduced risk of fatal colon cancer", N Engl J Med, 325, pp.1593~1596 (1991)
- Giardiello FM, "Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis", N Engl J Med, 328, pp.1313~1316 (1993)
- Cornetta AJ, "Cyclooxygenase- 2 expression in human thyroid carcinoma and Hashimoto’s thyroiditis", Laryngoscope, 112, pp.238~242 (2002)
- Singh B, "Coexistent Hashimoto’s thyroiditis with papillary thyroid carcinoma: impact on presentation, management, and outcome", Surgery, 126, pp.1070~1076 (1999)
- Tamimi DM, "The association between chronic lymphocytic thyroiditis and thyroid tumors", Int J Surg Pathol, 10, pp.141~146 (2002)
- Sawaoka H, "Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice", Am J Physiol, 274(6 Pt 1), pp.G1061~G1067 (1998)
- Liu XH, "NS398, a selective cyclooxygenase- 2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells", Cancer Res, 58, pp.4245~4249 (1998)
- Sawaoka H, "Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo", Lab Invest, 79, pp.1469~1477 (1999)
- Williams CS, "Host cyclooxygenase- 2 modulates carcinoma growth", J Clin Invest, 105, pp.1589~1594 (2000)
- Dannenberg AJ, "Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer", Lancet Oncol, 2, pp.544~551 (2001)
- Russell JP, "Proinflammatory mediators and genetic background in oncogene mediated tumor progression", J Immunol, 172, pp.4059~4067 (2004)
- Portier CJ, "Endocrine dismodulation and cancer", Neuro Endocrinol Lett, 23(Suppl 2), pp.43~47 (2002)
- Nose F, "Up-regulation of cyclooxygenase- 2 expression in lymphocytic thyroiditis and thyroid tumors: significant correlation with inducible nitric oxide synthase", Am J Clin Pathol, 117, pp.546~551 (2002)
- Prescott SM, "Cyclooxygenase-2 and carcinogenesis", Biochim Biophys Acta, 1470, pp.M69~M78 (2000)
- Berg J, "Inducible cyclooxygenase-2 gene expression in the human thyroid epithelial cell line Nthy-ori3-1", Inflamm Res, 49, pp.139~143 (2000)
- Marquez-Bravo LG, "Differential expression of estrogen receptor alpha (ERalpha) protein in MCF-7 breast cancer cells chronically exposed to TCDD", J Cell Biochem, 103, pp.636~647 (2008)
- Chao HR, "Arsenic inhibits induction of cytochrome P450 1A1 by 2,3,7,8-tetrachlorodibenzo-p-dioxin in human hepatoma cells", J Hazard Mater, 137, pp.716~722 (2006)
- Kwon MJ, "2,3,7,8-Tetrachlorodibenzo-pdioxin (TCDD)-induced activation of mitogen-activated protein kinase signaling pathway in Jurkat T cells", Pharmacol Toxicol, 93, pp.186~190 (2003)